David W. Boulton

7.1k total citations · 1 hit paper
146 papers, 5.0k citations indexed

About

David W. Boulton is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, David W. Boulton has authored 146 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Endocrinology, Diabetes and Metabolism, 46 papers in Surgery and 32 papers in Molecular Biology. Recurrent topics in David W. Boulton's work include Diabetes Treatment and Management (76 papers), Pancreatic function and diabetes (38 papers) and Diabetes Management and Research (25 papers). David W. Boulton is often cited by papers focused on Diabetes Treatment and Management (76 papers), Pancreatic function and diabetes (38 papers) and Diabetes Management and Research (25 papers). David W. Boulton collaborates with scholars based in United States, Sweden and Poland. David W. Boulton's co-authors include Frank LaCreta, C. Lindsay DeVane, Sreeneeranj Kasichayanula, J. Paul Fawcett, Steven C. Griffen, John S. Markowitz, Peter J. Greasley, Marc Pfister, Xiaoni Liu and Thomas Walle and has published in prestigious journals such as SHILAP Revista de lepidopterología, Analytical Chemistry and Diabetes Care.

In The Last Decade

David W. Boulton

140 papers receiving 4.8k citations

Hit Papers

Why do SGLT2 inhibitors r... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
    2017 355 citations David W. Boulton et al. Diabetes Obesity and Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David W. Boulton United States 39 2.6k 1.6k 1.4k 630 610 146 5.0k
Munehiro Kitada Japan 46 1.5k 0.6× 2.4k 1.5× 892 0.7× 446 0.7× 742 1.2× 121 7.0k
Pamela Maffioli Italy 42 2.4k 0.9× 2.0k 1.3× 974 0.7× 1.1k 1.7× 252 0.4× 188 6.4k
Giuseppe Derosa Italy 54 4.2k 1.6× 3.1k 2.0× 1.8k 1.3× 1.7k 2.7× 343 0.6× 337 10.5k
Peter W. Stacpoole United States 53 908 0.4× 4.5k 2.9× 917 0.7× 245 0.4× 553 0.9× 225 9.5k
Garry G. Graham Australia 31 670 0.3× 1.3k 0.8× 945 0.7× 977 1.6× 678 1.1× 115 5.0k
Aziz Karim United States 37 804 0.3× 1.2k 0.8× 551 0.4× 1.2k 1.9× 668 1.1× 127 5.5k
Stefano Bellosta Italy 34 706 0.3× 2.4k 1.5× 2.8k 2.1× 529 0.8× 498 0.8× 94 7.3k
Giovambattista Desideri Italy 46 1.9k 0.7× 1.3k 0.8× 1.2k 0.9× 409 0.6× 146 0.2× 216 7.7k
Hong‐Hao Zhou China 38 432 0.2× 1.3k 0.8× 545 0.4× 567 0.9× 1.3k 2.1× 165 4.7k
Kyoung‐Ah Kim South Korea 35 448 0.2× 1.1k 0.7× 432 0.3× 562 0.9× 840 1.4× 122 3.7k

Countries citing papers authored by David W. Boulton

Since Specialization
Citations

This map shows the geographic impact of David W. Boulton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David W. Boulton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David W. Boulton more than expected).

Fields of papers citing papers by David W. Boulton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David W. Boulton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David W. Boulton. The network helps show where David W. Boulton may publish in the future.

Co-authorship network of co-authors of David W. Boulton

This figure shows the co-authorship network connecting the top 25 collaborators of David W. Boulton. A scholar is included among the top collaborators of David W. Boulton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David W. Boulton. David W. Boulton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Penland, Robert C., et al.. (2025). Model-based Comparison of the Pharmacokinetic/Pharmacodynamic and Eosinophilic Response of Benralizumab Versus Depemokimab at 12 Weeks. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A2502–A2502.
2.
Bertagnolli, Lynn N., et al.. (2024). A literature review of drug transport mechanisms during lactation. CPT Pharmacometrics & Systems Pharmacology. 13(11). 1870–1880. 14 indexed citations
3.
Sharma, Pradeep, David W. Cheung, Weifeng Tang, et al.. (2024). Inhibition of OATP1B1/3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration. Clinical Pharmacology & Therapeutics. 118(2). 497–509. 3 indexed citations
4.
5.
Sokolov, Victor, et al.. (2023). A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes. CPT Pharmacometrics & Systems Pharmacology. 12(6). 831–841. 4 indexed citations
6.
Tang, Weifeng, Raj Tummala, J.O. Almquist, et al.. (2023). Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab. Clinical Pharmacokinetics. 62(5). 655–671. 6 indexed citations
7.
Bertagnolli, Lynn N., et al.. (2023). A Literature Review of Changes in Phase II Drug-Metabolizing Enzyme and Drug Transporter Expression during Pregnancy. Pharmaceutics. 15(11). 2624–2624. 10 indexed citations
8.
Tang, Weifeng, Carlos Fernández‐Teruel, Matilde Merino‐Sanjuán, et al.. (2023). Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies. British Journal of Clinical Pharmacology. 89(9). 2691–2702. 1 indexed citations
9.
Clegg, Lindsay E., Yankang Jing, Robert C. Penland, et al.. (2021). Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR‐TIMI 53 cardiovascular outcomes trials. Diabetes Obesity and Metabolism. 23(5). 1101–1110. 5 indexed citations
10.
Clegg, Lindsay E., Adrian F. Hernandez, George L. Bakris, et al.. (2020). Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. Diabetes Obesity and Metabolism. 22(5). 798–806. 12 indexed citations
11.
Clegg, Lindsay E., Robert C. Penland, David W. Boulton, et al.. (2020). Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial. Diabetes Obesity and Metabolism. 22(12). 2493–2498. 25 indexed citations
12.
13.
Boulton, David W., Georgia Kollia, Suresh Mallikaarjun, & David M. Kornhauser. (2012). Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole. Journal of Clinical Pharmacy and Therapeutics. 37(5). 565–570. 9 indexed citations
14.
Boulton, David W., Georgia Kollia, Suresh Mallikaarjun, & David M. Kornhauser. (2012). Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole. Journal of Clinical Pharmacy and Therapeutics. 1 indexed citations
15.
Kasichayanula, Sreeneeranj, Xuejun Liu, W. Zhang, et al.. (2011). Effect of a high‐fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obesity and Metabolism. 13(8). 770–773. 39 indexed citations
16.
Vachharajani, Nimish N., et al.. (2011). The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase. British Journal of Clinical Pharmacology. 72(5). 775–786. 5 indexed citations
17.
Findling, Robert L., Ralph E. Kauffman, Floyd R. Sallee, et al.. (2009). An Open-Label Study of Aripiprazole: Pharmacokinetics, Tolerability, and Effectiveness in Children and Adolescents with Conduct Disorder. Journal of Child and Adolescent Psychopharmacology. 19(4). 431–439. 38 indexed citations
18.
Boulton, David W., Angela Tang, Chirag Patel, et al.. (2009). Pharmacokinetics of the dipeptidyl peptidase-4 inhibitor saxagliptin in subjects with renal impairment. 20. 7 indexed citations
19.
Boulton, David W., et al.. (2001). A single dose of methadone inhibits cytochrome P‐4503A activity in healthy volunteers as assessed by the urinary cortisol ratio. British Journal of Clinical Pharmacology. 51(4). 350–354. 17 indexed citations
20.
Boulton, David W., et al.. (1994). The stability of an enalapril maleate oral solution prepared from tablets. The Australian Journal of Hospital Pharmacy. 24(2). 151–156. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Munehiro Kitada Breakdown of academic impact, for papers by Pamela Maffioli Breakdown of academic impact, for papers by Giuseppe Derosa Breakdown of academic impact, for papers by Peter W. Stacpoole Breakdown of academic impact, for papers by Garry G. Graham Breakdown of academic impact, for papers by Aziz Karim Breakdown of academic impact, for papers by Stefano Bellosta Breakdown of academic impact, for papers by Giovambattista Desideri Breakdown of academic impact, for papers by Hong‐Hao Zhou Breakdown of academic impact, for papers by Kyoung‐Ah Kim
Rankless by CCL
2026